AN INNOVATIVE PLATFORM FOR THE DEVELOPMENT OF VASCULAR REHABILITATION TECHNOLOGIES
AN INNOVATIVE PLATFORM FOR THE DEVELOPMENT OF VASCULAR REHABILITATION TECHNOLOGIES
VISION
Through its disruptive approach Dyverto aims at improving Patient’s lives via solutions that are both Clinically and Economically sustainable.
VISION
Through its disruptive approach Dyverto aims at improving Patient’s lives via solutions that are both Clinically and Economically sustainable.
THE APPROACH
Dyverto has developed – and preliminarily tested – a first device (Dyve_Mesh) aimed at preventing the progression of early-stage abdominal aortic aneurysms (AAA).
In the words of one of the investigators, “Dyverto’s approach has the potential to representing a game-changer in the way AAA are treated today as it tackles the progression of the disease instead of focusing simply on addressing its consequences”.
An ANEURYSM is an abnormal dilatation in an artery, determined by weakening of the vascular wall, in turn caused – among other factors – by disturbed hemodynamics.
Existing guidelines recommend treatment of diagnosed abdominal aortic aneurysms when they reach a size larger than 5,5cm.
In the US only, more than one million diagnosed patients are (nervously) waiting for their aneurysms to grow to such “critical” size so they can be treated.
About 15.000 die every year for an aneurysm that will suddenly rupture.
VISION
Through its disruptive approach Dyverto aims at improving Patient’s lives via solutions that are both Clinically and Economically sustainable.
VISION
Through its disruptive approach Dyverto aims at improving Patient’s lives via solutions that are both Clinically and Economically sustainable.
THE APPROACH
Dyverto has developed – and preliminarily tested – a first device (Dyve_Mesh) aimed at preventing the progression of early-stage abdominal aortic aneurysms (AAA).
In the words of one of the investigators, “Dyverto’s approach has the potential to representing a game-changer in the way AAA are treated today as it tackles the progression of the disease instead of focusing simply on addressing its consequences”.
An ANEURYSM is an abnormal dilatation in an artery, determined by weakening of the vascular wall, in turn caused – among other factors – by disturbed hemodynamics.
Existing guidelines recommend treatment of diagnosed abdominal aortic aneurysms when they reach a size larger than 5,5cm.
In the US only, more than one million diagnosed patients are (nervously) waiting for their aneurysms to grow to such “critical” size so they can be treated.
About 15.000 die every year for an aneurysm that will suddenly rupture.
THE APPROACH
Dyverto has developed – and preliminarily tested – a first device (Dyve_Mesh) aimed at preventing the progression of early-stage abdominal aortic aneurysms (AAA).
In the words of one of the investigators, “Dyverto’s approach has the potential to representing a game-changer in the way AAA are treated today as it tackles the progression of the disease instead of focusing simply on addressing its consequences”.
An ANEURYSM is an abnormal dilatation in an artery, determined by weakening of the vascular wall, in turn caused – among other factors – by disturbed hemodynamics.
Existing guidelines recommend treatment of diagnosed abdominal aortic aneurysms when they reach a size larger than 5,5cm.
In the US only, more than one million diagnosed patients are (nervously) waiting for their aneurysms to grow to such “critical” size so they can be treated.
About 15.000 die every year for an aneurysm that will suddenly rupture.
THE DEVICE
Dyverto’s device may represent an effective tool to prevent the evolution of the disease by stabilizing hemodynamics before an aneurysm reaches its “critical size”.
Unlike a conventional stent-graft that merely excludes the diseased area by inserting a tube inside it, Dyverto’s working principle is to eliminate disturbed hemodynamics by re-establishing physiological orderly-channeled blood whilst allowing uninterrupted perfusion of side vessels.
Lastly, Dyverto’s patented technology represents a versatile platform for a variety of prospective applications both within and outside the cardiovascular field.
A unique design and construction creates a souple, low profile and adaptable device that guarantees a truly minimally invasive approach and facilitates navigation through hostil anatomies
The self expanding Nitinol multylayer construction has been developed thinking of the properties of the arterial tunica media.
THE DEVICE
Dyverto’s device may represent an effective tool to prevent the evolution of the disease by stabilizing hemodynamics before an aneurysm reaches its “critical size”.
Unlike a conventional stent-graft that merely excludes the diseased area by inserting a tube inside it, Dyverto’s working principle is to eliminate disturbed hemodynamics by re-establishing physiological orderly-channeled blood whilst allowing uninterrupted perfusion of side vessels.
Lastly, Dyverto’s patented technology represents a versatile platform for a variety of prospective applications both within and outside the cardiovascular field.
A unique design and construction creates a souple, low profile and adaptable device that guarantees a truly minimally invasive approach and facilitates navigation through hostil anatomies
The self expanding Nitinol multylayer construction has been developed thinking of the properties of the arterial tunica media.
THE DEVICE
Dyverto’s device may represent an effective tool to prevent the evolution of the disease by stabilizing hemodynamics before an aneurysm reaches its “critical size”.
Unlike a conventional stent-graft that merely excludes the diseased area by inserting a tube inside it, Dyverto’s working principle is to eliminate disturbed hemodynamics by re-establishing physiological orderly-channeled blood whilst allowing uninterrupted perfusion of side vessels.
Lastly, Dyverto’s patented technology represents a versatile platform for a variety of prospective applications both within and outside the cardiovascular field.
A unique design and construction creates a souple, low profile and adaptable device that guarantees a truly minimally invasive approach and facilitates navigation through hostil anatomies
The self expanding Nitinol multylayer construction has been developed thinking of the properties of the arterial tunica media.
THE DEVICE
Dyverto’s device may represent an effective tool to prevent the evolution of the disease by stabilizing hemodynamics before an aneurysm reaches its “critical size”.
Unlike a conventional stent-graft that merely excludes the diseased area by inserting a tube inside it, Dyverto’s working principle is to eliminate disturbed hemodynamics by re-establishing physiological orderly-channeled blood whilst allowing uninterrupted perfusion of side vessels.
Lastly, Dyverto’s patented technology represents a versatile platform for a variety of prospective applications both within and outside the cardiovascular field.
A unique design and construction creates a souple, low profile and adaptable device that guarantees a truly minimally invasive approach and facilitates navigation through hostil anatomies.
The self expanding Nitinol multylayer construction has been developed thinking of the properties of the arterial tunica media.
THE TEAM
The team behind the project assembles a vast array of clinical, technical and business experience in the cardio-vascular field.
Davide Bianchi – (Chairman of the Board)
Senior executive and entrepreneur with over 30 years of global experience in Medical Devices. Business angel and strategic advisor for several PEs and VCs with a broad experienced in M&As. Currently serves as Chairman of the Board @ Corcym Holding SA and as OAP @ Gyrus Capital.
Massimo Gilmozzi – (CEO)
He has a solid background in the cardiovascular field, with over 20 years of experience in senior roles with J&J and WLGore & Associates, both in Europe and in the US. He has developed strong entrepreneurial and consulting skills, managing complex projects in multiple industries.
Prof. Alessandro Bortone - (Inventor and Scientific Advisor)
Adjunct Professor; Head of Operational Unit for Interventional Hemodynamics of Cardiosurgery; Coordinator of Interventional Hemodynamic Laboratories affiliated to the Cardiothoracic Department; Director of the Interdepartmental Project Unit of Interventional Hemodynamics of the University Hospital Policlinico di Bari.
Prof. Gianluca Faggioli - (Principal Investigator for aortic applications)
Full Professor of Vascular Surgery, Director of the Residency Program in Vascular Surgery @ Alma Mater Studiorum, University of Bologna, Italy. Carries out clinical and research activities in all fields of Vascular Surgery, with particular interest in supraortic vascular disease, aortic aneurysms, peripheral arterial disease and chronic venous insufficiency.
Prof. Maria Laura Bacci - (Principal Investigator for animal modeling development)
Full Professor in Veterinary Physiology @ Bologna University, Head of the departmental unit ASA “Allevamento e Sperimentazione Animale” (Animal Breeding and Experimentation); President of Scientific Committee of SISVET, Italian Society of Veterinary Sciences. Deputy Director of DIMEVET and Deputy Dean of the School of Agriculture and Veterinary Medicine – Ozzano dell’Emilia.
THE TEAM
The team behind the project assembles a vast array of clinical, technical and business experience in the cardio-vascular field.
Davide Bianchi – (Chairman of the Board)
Senior executive and entrepreneur with over 30 years of global experience in Medical Devices. Business angel and strategic advisor for several PEs and VCs with a broad experienced in M&As. Currently serves as Chairman of the Board @ Corcym Holding SA and as OAP @ Gyrus Capital.
Massimo Gilmozzi – (CEO)
He has a solid background in the cardiovascular field, with over 20 years of experience in senior roles with J&J and WLGore & Associates, both in Europe and in the US. He has developed strong entrepreneurial and consulting skills, managing complex projects in multiple industries.
Prof. Alessandro Bortone - (Inventor and Scientific Advisor)
Assistant Professor in Cardiology; Head of Operational Unit for Interventional Hemodynamics of Cardiosurgery; Coordinator of Interventional Hemodynamic Laboratories affiliated to the Cardiothoracic Department; Director of the Interdepartmental Project Unit of Interventional Hemodynamics of the University Hospital Policlinico di Bari – Italy. Policlinico di Bari.
Prof. Gianluca Faggioli - (Principal Investigator for aortic applications)
Full Professor of Vascular Surgery, Director of the Residency Program in Vascular Surgery @ Alma Mater Studiorum, University of Bologna, Italy. Carries out clinical and research activities in all fields of Vascular Surgery, with particular interest in supraortic vascular disease, aortic aneurysms, peripheral arterial disease and chronic venous insufficiency.
Prof. Maria Laura Bacci - (Principal Investigator for animal modeling development)
Full Professor in Veterinary Physiology @ Bologna University, Head of the departmental unit ASA “Allevamento e Sperimentazione Animale” (Animal Breeding and Experimentation); President of Scientific Committee of SISVET, Italian Society of Veterinary Sciences. Deputy Director of DIMEVET and Deputy Dean of the School of Agriculture and Veterinary Medicine – Ozzano dell’Emilia.
THE TEAM
Davide Bianchi – (Chairman of the Board)
Senior executive and entrepreneur with over 30 years of global experience in Medical Devices. Business angel and strategic advisor for several PEs and VCs with a broad experienced in M&As. Currently serves as Chairman of the Board @ Corcym Holding SA and as OAP @ Gyrus Capital.
Massimo Gilmozzi – (CEO)
He has a solid background in the cardiovascular field, with over 20 years of experience in senior roles with J&J and WLGore & Associates, both in Europe and in the US. He has developed strong entrepreneurial and consulting skills, managing complex projects in multiple industries.
Prof. Alessandro Bortone - (Inventor and Scientific Advisor)
Adjunct Professor; Head of Operational Unit for Interventional Hemodynamics of Cardiosurgery; Coordinator of Interventional Hemodynamic Laboratories affiliated to the Cardiothoracic Department; Director of the Interdepartmental Project Unit of Interventional Hemodynamics of the University Hospital Policlinico di Bari.
Prof. Gianluca Faggioli - (Principal Investigator for aortic applications)
Full Professor of Vascular Surgery, Director of the Residency Program in Vascular Surgery @ Alma Mater Studiorum, University of Bologna, Italy. Carries out clinical and research activities in all fields of Vascular Surgery, with particular interest in supraortic vascular disease, aortic aneurysms, peripheral arterial disease and chronic venous insufficiency.
Prof. Maria Laura Bacci - (Principal Investigator for animal modeling development)
Full Professor in Veterinary Physiology @ Bologna University, Head of the departmental unit ASA “Allevamento e Sperimentazione Animale” (Animal Breeding and Experimentation); President of Scientific Committee of SISVET, Italian Society of Veterinary Sciences. Deputy Director of DIMEVET and Deputy Dean of the School of Agriculture and Veterinary Medicine – Ozzano dell’Emilia.
THE TEAM
Davide Bianchi – (Chairman of the Board)
Senior executive and entrepreneur with over 30 years of global experience in Medical Devices. Business angel and strategic advisor for several PEs and VCs with a broad experienced in M&As. Currently serves as Chairman of the Board @ Corcym Holding SA and as OAP @ Gyrus Capital.
Massimo Gilmozzi – (CEO)
He has a solid background in the cardiovascular field, with over 20 years of experience in senior roles with J&J and WLGore & Associates, both in Europe and in the US. He has developed strong entrepreneurial and consulting skills, managing complex projects in multiple industries.
Prof. Alessandro Bortone - (Inventor and Scientific Advisor)
Adjunct Professor; Head of Operational Unit for Interventional Hemodynamics of Cardiosurgery; Coordinator of Interventional Hemodynamic Laboratories affiliated to the Cardiothoracic Department; Director of the Interdepartmental Project Unit of Interventional Hemodynamics of the University Hospital Policlinico di Bari.
Prof. Gianluca Faggioli - (Principal Investigator for aortic applications)
Full Professor of Vasculare Surgery, Director of the Residency Program in Vascular Surgery @ Alma Mater Studiorum, University of Bologna, Italy. Carries out clinical and research activities in all fields of Vascular Surgery, with particular interest in supraortic vascular disease, aortic aneurysms, peripheral arterial disease and chronic venous insufficiency.
Prof. Maria Laura Bacci - (Principal Investigator for animal modeling development)
Full Professor in Veterinary Physiology @ Bologna University, Head of the departmental unit ASA “Allevamento e Sperimentazione Animale” (Animal Breeding and Experimentation); President of Scientific Committee of SISVET, Italian Society of Veterinary Sciences. Deputy Director of DIMEVET and Deputy Dean of the School of Agriculture and Veterinary Medicine – Ozzano dell’Emilia.
INVESTORS
Davide Bianchi
Davide Bianchi is an investor and entrepreneur bringing more than 30 years of experience in the med-tech arena with senior positions at leading companies such as WLGore, Edwards LS, Sorin/Livanova and Orthofix.
Cardiovascular Lab is the first incubator in Europe fully dedicated to the cardiovascular field, scouting and developing innovative ideas coming from the clinical experience. CVLAb takes the most promising ones through patenting, prototyping and proof-of-concept, all the way to spinning-off a new company and seeking venture capital funding.
Nocturnal Labs is an operational holding company that supports seed-stage companies to develop products, technologies, and global businesses that advance health.
INVESTORS
Davide Bianchi
Davide Bianchi is an investor and entrepreneur bringing more than 30 years of experience in the med-tech arena with senior positions at leading companies such as WLGore, Edwards LS, Sorin/Livanova and Orthofix.
Cardiovascular Lab is the first incubator in Europe fully dedicated to the cardiovascular field, scouting and developing innovative ideas coming from the clinical experience. CVLAb takes the most promising ones through patenting, prototyping and proof-of-concept, all the way to spinning-off a new company and seeking venture capital funding.
Nocturnal Labs is an operational holding company that supports seed-stage companies to develop products, technologies, and global businesses that advance health.
INVESTORS
Mt-lab is an operational holding company that supports seed-stage companies to develop products, technologies, and global businesses that advance health.
Cardiovascular Lab is the first incubator in Europe fully dedicated to the cardiovascular field, scouting and developing innovative ideas coming from the clinical experience. CVLAb takes the most promising ones through patenting, prototyping and proof-of-concept, all the way to spinning-off a new company and seeking venture capital funding.
Davide Bianchi
Davide Bianchi is an investor and entrepreneur bringing more than 30 years of experience in the med-tech arena with senior positions at leading companies such as WLGore, Edwards LS, Sorin/Livanova and Orthofix.
INVESTORS
Nocturnal Labs is an operational holding company that supports seed-stage companies to develop products, technologies, and global businesses that advance health.
Nocturnal Labs is an operational holding company that supports seed-stage companies to develop products, technologies, and global businesses that advance health.
Davide Bianchi
Davide Bianchi is an investor and entrepreneur bringing more than 30 years of experience in the med-tech arena with senior positions at leading companies such as WLGore, Edwards LS, Sorin/Livanova and Orthofix.